Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi buddy, Hope all is well. I'm still in $BLDV and $SHMN
$90 Billion In Investments Into EVs & Batteries Now Pledged By Global Auto Manufacturers
http://lithium-news.com/2017/12/03/lithium-juniors-could-rally-following-teslas-interest-in-argentina/
Thanks, I like them guys. Wish i had there money!
SQM talks down lithium oversupply, says market to grow 80% a year
http://www.mining.com/sqm-talks-lithium-oversupply-says-market-grow-80-year/?utm_source=digest-en-mining-180301&utm_medium=email&utm_campaign=digest
Thanks wow, Have a nice weekend!
$PVCT,
Newspaper Article Reports Clinical Trial Subject's Experience with PV-10
Thursday February 22, 2017
On February 16, 2018, an article was published in the Adelaide, Australia newspaper The Advertiser describing the experiences of the two patients participating in the Provectus-sponsored clinical trial, "A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumors Metastatic to the Liver" (NCT02693067).
The video article is available from The Advertiser website at:
http://www.adelaidenow.com.au/news/south-australia/cancer-drug-rose-bengal-lets-michael-button-walk-daughter-down-the-aisle/news-story/98f49f66a47d733130a20efadae15e29
Cancer drug Rose Bengal lets Michael Button walk daughter down the aisle
$PVCT news,
Provectus Biopharmaceuticals Provides Update on GI Cancer Program for Investigational Drug PV-10
Thursday February 22, 2018
- Current Phase 1 basket study continues to enroll and treat patients for HCC and liver cancer metastases (colorectal, lung, pancreatic, melanoma, ovarian, and breast); updated data presentation planned for 2018 -
- First expansion of GI cancer program, Phase 1 study of PV-10 for symptomatic NET metastatic to liver, has now treated multiple patients; preliminary data presentation planned for 2018 -
- Projected second program expansion: Phase 1b/2 study of PV-10 neoadjuvant to chemotherapy for metastatic pancreatic cancer -
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing the first small molecule oncolytic immunotherapy for solid tumor cancers, today provided an update on the Company's gastrointestinal ("GI") cancer clinical development program for its lead investigational drug PV-10, which is administered percutaneously when targeting GI cancer tumors.
Provectus' Phase 1 study of patients with hepatic lesions (a "basket study" open to patients with different hepatic tumor types and entitled A Study to Assess PV-10 Chemoablation of Cancer of the Liver, NCT00986661) has treated 18 patients at four U.S. sites to date: six patients with hepatocellular carcinoma ("HCC"), six patients with metastatic colorectal cancer ("mCRC") metastatic to the liver, and six patients with breast cancer, lung cancer, melanoma, ovarian cancer or pancreatic cancer liver metastases. A fifth U.S. site is currently projected to enroll patients in the first half of 2018 and focus on uveal melanoma metastatic to the liver.
The most recent data from this basket study was presented at the 9th Annual Symposium of Clinical Interventional Oncology ("CIO") in Hollywood, Florida on February 4-5, 2017 (a similar presentation was made at the 26th Conference of the Asian Pacific Association for the Study of the Liver in Shanghai, China on February 15-19, 2017). Results included:
Two of six patients with HCC who remained alive for 58 and 75 months after treatment, the latter with no evidence of disease;
Four of five patients with mCRC liver metastases who remained alive 9 to 73 months after treatment, including one patient with no evidence of disease at 73 months; and
One patient with pancreatic cancer liver metastases who remained alive 12 months after treatment.
Evidence of tumor destruction in both target (injected) and bystander (non-injected) lesions was displayed. A copy of the CIO poster presentation is available on Provectus' website. Provectus currently plans to present updated data from this basket study at a medical conference in the second half of 2018.
In February 2017, researchers at the University of Illinois at Chicago published work elucidating PV-10's mechanism of action in colon cancer, whereby PV-10 may induce immunogenic cell death that contributes to specific antitumor immunity.1
In April 2017, the first patient was treated in the Company's first expansion trial of the GI cancer program (A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumors Metastatic to the Liver, NCT02693067). The patient, who had multifocal disease refractory to Lutate (177Lu-DOTA-octreotate, a radio-labelled somatostatin analog; also known as LUTATHERA®, which was approved earlier this month by the U.S. Food and Drug Administration), received percutaneous PV-10 to a single neuroendocrine tumor ("NET") metastasis, and subsequently received a second injection of PV-10 to a second NET metastasis.2 Since then, a second patient received a first injection.2 Provectus currently plans to present preliminary data from this study at a medical conference in the second half of 2018.
Provectus is planning to initiate a second expansion of its GI cancer program focused on metastatic pancreatic cancer. This new study will be the first clinical combination use of PV-10 in GI cancer:
The study, with the preliminary title A Phase 1b/2 study of percutaneous PV-10 neoadjuvant to chemotherapy for metastatic pancreatic cancer, builds on the data from the Company's hepatic basket and NET trials to address pancreatic cancer that has metastasized to the liver. Prior preclinical work by Moffitt Cancer Center established that PV-10 has therapeutic activity in pancreatic cancer murine models as both a single agent and in combination with gemcitabine, a standard chemotherapeutic agent used to treat this disease.3
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "GI cancers as a group are responsible for more deaths than any other disease type. Provectus and its research collaborators have independently established PV-10 as an oncolytic immunotherapy in melanoma4, colon cancer, and pancreatic cancer. We will expand our GI cancer clinical development program by continuing to initiate trials where PV-10, either as a single agent or in combination with another class of agent, may address multiple different indications with substantial unmet need or that are rare diseases."
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Intralesional PV-10, the first small molecule oncolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers like melanoma and cancers of the liver as well as preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses like psoriasis; pathways significantly improved by PH-10 treatment include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22 and interferons. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016).
References:
1. Qin J., Kunda N., Qiao G., Calata J.F., Pardiwala K., Prabhakar B.S., Maker A.V. (2017), Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017 Feb 2;8(2):e2584. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386459/.
2. On February 16, 2018, an article was published in the Adelaide, Australia newspaper The Advertiser describing the experiences of the two patients participating in the Phase 1 NET study. DISCLAIMER: In linking to the article Provectus makes no claims about the safety or efficacy of investigational drug PV-10.
3. Pilon-Thomas S., Weber A., Morse J., Kodumudi, K., Liu H., Mullinax J., Sarnaik A.A., (2016), Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer. Journal for ImmunoTherapy of Cancer 2016 4(Suppl 1):73. https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0173-6.
4. Liu H., Innamarato P.P., Kodumudi K., Weber A., Nemoto S., Robinson J.L., Crago G., McCardle T., Royster E., Sarnaik A.A., Pilon-Thomas S. (2016), Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget, 7:37893–37905. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122358/.
Trademark:
LUTATHERA® is a registered trademark of Advanced Accelerator Applications S.A., Saint-Genis-Pouilly, France.
Contact:
Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.
President
Phone: 866-594-5999
Southern Copper wins auction for massive Peru copper project
http://www.mining.com/rio-teck-hudbay-among-bidders-massive-peru-copper-project/?utm_source=digest-en-mining-180220&utm_medium=email&utm_campaign=digest
Copper, iron ore price jump sparks rally in mining stocks
http://www.mining.com/copper-iron-ore-price-jump-sparks-rally-mining-stocks/?utm_source=digest-en-mining-180214&utm_medium=email&utm_campaign=digest
Hey buddy, what is your thoughts on $ONCI?
Hey buddy glad to see you here, I think $SHMN going to be a good one!
Rio Tinto back in race for stake in world’s largest lithium miner
http://www.mining.com/rio-tinto-back-race-stake-worlds-largest-lithium-miner/?utm_source=digest-en-mining-180202&utm_medium=email&utm_campaign=digest
Dow industrial heads for biggest weekly point setback in 9 years, weekly drop of 1,100
https://www.marketwatch.com/story/the-dow-industrials-have-tumbled-730-points-this-week-its-worst-point-loss-in-2-years-2018-02-02
Goldman all but says the mining supercycle is back
http://www.mining.com/goldman-says-mining-supercycle-back/?utm_source=digest-en-mining-180201&utm_medium=email&utm_campaign=digest
How you doing buddy? I have been really busy fixing and selling cars.
These are top-10 global mining trends expected for 2018
http://www.mining.com/top-10-global-mining-trends-expected-2018/?utm_source=digest-en-mining-180131&utm_medium=email&utm_campaign=digest
Bidders for $500m Canada streaming deal as cobalt price surges–report
http://www.mining.com/bidders-500m-canada-streaming-deal-cobalt-price-surges-report/?utm_source=digest-en-mining-180130&utm_medium=email&utm_campaign=digest
CHART: Hedge funds have never been this bullish about oil
http://www.mining.com/chart-hedge-funds-never-bullish-oil/?utm_source=digest-en-mining-180129&utm_medium=email&utm_campaign=digest
Great call buddy, $HAON 0.0007 0.00 0.00 1,000,000 0.0006 0.0007
Alerted @ 1.03, Upward slowly $APHB 1.1748 0.0848 +7.78 569,925 1.17 1.18
Don't apologize for nothing buddy, We made money twice so far.
Thanks for the updates!
Got a date? lol
Nice call, $HMNY 8.89 1.73 +24.16 9,347,954 8.84 8.86
On watch, $APHB 1.03 -0.47 -31.33 1,700,001 1.03 1.04
Looks like bottomed, $MGTI 4.50 0.00 0.00 125,655 4.49 4.50
Junior Lithium Miners See Big Upside As China Moves To Secure Lithium Supplies
https://streetsignals.com/standard-lithium/sll-9/junior-lithium-miners-see-big-upside-as-china-moves-to-secure-lithium-supplies/?utm_source=facebook&utm_medium=paid_social&utm_campaign=facebook_SLL_Big-Upside_Quote-Pages_55-65-M-US-CA_auto-boost_c_300382
Heat wave today, Near 30 degrees. Nice!
Welcome back, Long, long time.
https://investorshub.advfn.com/Nasdaq-Dip-&-Rip-32462/
Honest answer, I'm not sure about anything right now. lol
Mining in 2018: Copper price to power on
http://www.mining.com/mining-2018-copper-price-power/?utm_source=digest-en-mining-180102&utm_medium=email&utm_campaign=digest
Up over 100% since alerted, $PVCT 0.087 0.005 +6.10 1,250,627 0.085 0.087
IMO still moving to .28
Have a happy and safe New Years!
lol, good night, have fun!
Get your new computer up and running?
$PVCT 0.074 0.008 +12.12 2,147,884 0.071 0.074
$ADVT 0.0193 0.0028 +16.97 4,141,224 0.019 0.0193
$PVCT,
Provectus News
First Study of Quality of Life of Patients with Locally Advanced Cutaneous Melanoma Published in Melanoma Research
- Emotional health/self-perception issues were most common; limitations of lifestyle and activities as well as coping strategies were also important -
- Provectus Biopharmaceuticals expands pivotal Phase 3 trial of intralesional PV-10 for this patient population to EU and LATAM; U.S. sites continue to enroll -
Wednesday December 27, 2017
KNOXVILLE, TN, /Globe Newswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that Melanoma Research (the "Journal") published results from a Provectus-sponsored study to understand the daily experiences of patients with locally advanced cutaneous melanoma. Physical and emotional experiences, symptom management, and subsequent impacts on quality of life historically have not been well understood or sufficiently described for this patient population.
The article may be accessed via the Journal's website under Published Ahead-of-Print at http://journals.lww.com/melanomaresearch/Abstract/publishahead/Quality_of_life_patient_reported_outcomes_for.99332.aspx.
Interviews of adults with Stage IIIB, IIIC or IV M1a cutaneous melanoma at three cancer centers in the U.S. (Moffitt Cancer Center, Tampa, Florida and Huntsman Cancer Institute, Salt Lake City, Utah) and Australia (Melanoma Institute Australia, Sydney) were conducted to assess how locoregionally advanced cutaneous melanoma impacted everyday life. According to the Journal article, "[e]motional health/self-perception issues were the most commonly identified (41% of patient impact expressions), including worry, concern, embarrassment, self-consciousness, fear, and thoughts of death. Limitations of lifestyle and activities were also identified (28% of expressions) including leisure and social activities, physical functioning, general functioning, and personal care. Coping strategies such as modified clothing choices, increased use of pain and/or anti-inflammatory medications, and avoidance/protection from the sun represented 20% of all impact expressions."
Study investigators "collected information on disease-specific patient-reported assessment of symptoms and quality of life (patient-reported outcomes, or PROs) that may provide a basis for supporting the clinical significance of objective response parameters such as progression-free survival (PFS) and complete response."
The Journal article also noted that "oth the US Food and Drug Administration and the European Medicines Agency have highlighted the value of establishing content validity in the development of tools to assess patient-reported outcomes. Such PRO-geared tools can extract critical concepts and impacts pertinent to the patient experience. Focus groups and interview sessions can be among those tools to elicit the patient experience."
Provectus previously supported Stage III melanoma patient advocacy efforts by the Melanoma Research Foundation ("MRF"):
A focus group, which addressed initial diagnosis, treatment, disease progression and the need for self-education and support; a summary of this group's outcome is available on Provectus' website at http://provectusbio.com/media/docs/MRF_Stage_III_Focus_Group_Summary_BRIEF_FINAL.pdf, and
MRF's Stage III Melanoma Patient Guide, which may be found on MRF's website at https://www.melanoma.org/understand-melanoma/cutaneous-melanoma/stage-iii-melanoma.
In its Summary Basis of Regulatory Action for IMLYGIC®1, the first intralesional therapy approved for melanoma, the U.S. Food and Drug Administration ("FDA") noted that "patients and their caregivers spoke of the value, both cosmetic and psychological, of watching their skin lesions disappear" during the April 2015 Joint Meeting of the Cellular, Tissue and Gene Therapies Advisory Committee and Oncologic Drugs Advisory Committee. The FDA also noted "[t]here may be associated psychological benefit, which may be substantial in patients who can see their visible lesions recede."
For patients with locally advanced cutaneous melanoma, Provectus is evaluating intralesional PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy (IMLYGIC) in an international, multi-center, pivotal Phase 3 trial (NCT02288897). In-transit, satellite and locally recurrent melanoma patients (Stage IIIB, IIIC or IV M1a) with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy (with BRAF or combined BRAF/MEK inhibitors) are eligible. The trial's primary endpoint is PFS (assessed via RECIST 1.1 every 12 weeks up to 18 months); complete response rate and overall survival are key secondary endpoints. PV-10 currently is or soon will be available at 19 clinical sites in five countries. The study is enrolling in Germany, Italy and the U.S., and clinical trial authorizations have been received for France and Mexico.
More information about this Phase 3 trial is available via ClinicalTrials.gov, the registry of clinical trials run by the U.S. National Library of Medicine at the National Institutes of Health ("NIH"), at https://clinicaltrials.gov/ct2/show/study/NCT02288897?term=Provectus%2C+PV-10&rank=6&show_locs=Y#locn.
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "Provectus has had a longstanding commitment to understanding quality of life issues in order to better design our clinical trials. We believe the endpoints of our pivotal Phase 3 trial for locally advanced cutaneous melanoma, like progression-free survival and complete response rate, are congruent with the findings of this quality of life study that highlight patients' emotional and physical challenges, which owe to their persistent, visible disease."
Mr. Rodrigues added, "We are grateful to our regulatory partners at FDA, Therapeutic Goods Administration, Agenzia Italiana del Farmaco, Bundesinstitut für Arzneimittel und Medizinprodukte, Agence Nationale de Sécurité du Médicament et des Produits de Santé, and Comisión Federal para la Protección contra Riesgos Sanitarios for working with Provectus to achieve clinical trial authorization in their respective countries for this important trial, and to enable the Company to continue the drug development work required to advance delivery of accessible and affordable healthcare around the globe via PV-10, the first small molecule oncolytic immunotherapy for melanoma."
The complete press release is available at http://www.provectusbio.com/news/press-releases/provectus-pr-20171227-1 on the Provectus